Clinical Trials Directory

Trials / Conditions / Recurrent Fallopian Tube Cancer

Recurrent Fallopian Tube Cancer

18 registered clinical trials studyying Recurrent Fallopian Tube Cancer — 1 currently recruiting.

StatusTrialSponsorPhase
WithdrawnStudy to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
NCT05126342
AGO Research GmbHPhase 2
Active Not RecruitingA Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive R
NCT05335993
CanariaBio Inc.Phase 2
RecruitingStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Rec
NCT03564340
Regeneron PharmaceuticalsPhase 1 / Phase 2
UnknownStudy of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
NCT02785250
ImmunoVaccine Technologies, Inc. (IMV Inc.)Phase 1 / Phase 2
CompletedMetformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone
NCT02122185
University of ChicagoPhase 2
WithdrawnVaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or
NCT01982487
Roswell Park Cancer InstitutePhase 1 / Phase 2
CompletedCarboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or R
NCT02046421
University of ChicagoPhase 1
TerminatedPaclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal C
NCT01962948
Fox Chase Cancer CenterPhase 1 / Phase 2
CompletedTivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01853644
Northwestern UniversityPhase 2
CompletedAuranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01747798
Mayo ClinicEARLY_Phase 1
CompletedSirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Pri
NCT01536054
Roswell Park Cancer InstitutePhase 1
CompletedCarboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT01652794
Case Comprehensive Cancer CenterPhase 1
CompletedStress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
NCT01764789
Ohio State University Comprehensive Cancer CenterN/A
TerminatedSJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did No
NCT01200797
National Cancer Institute (NCI)Phase 2
CompletedDecitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recur
NCT01673217
Roswell Park Cancer InstitutePhase 1
CompletedSunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal
NCT00388037
National Cancer Institute (NCI)Phase 2
CompletedCediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial,
NCT00278343
National Cancer Institute (NCI)Phase 2
WithdrawnMetformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tu
NCT02050009
Fox Chase Cancer CenterPhase 1